Department of Neurology, University Medical Center Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
Nat Rev Neurol. 2012 May 29;8(7):369-79. doi: 10.1038/nrneurol.2012.97.
Small-fibre neuropathy (SFN), a disorder of thinly myelinated Aδ-fibres and unmyelinated C-fibres, is clinically characterized by neuropathic pain symptoms and autonomic complaints. Diagnosis of SFN is challenging as the clinical picture can be difficult to interpret and results from nerve conduction studies are often normal. In cases of suspected SFN, measurement of intraepidermal nerve fibre density and/or analysis of quantitative sensory testing can enable diagnosis. New diagnostic techniques (including measurement of nerve fibre density using corneal confocal microscopy, and nociceptive evoked potentials) may contribute to the diagnostic work-up. SFN can be associated with systemic diseases such as immune-mediated disorders, but remains idiopathic in a substantial proportion of patients. Gain-of-function variants in the Na(v)1.7 sodium channel have recently been found in nearly 30% of patients with idiopathic SFN, but the mechanisms of axonal degeneration in the disorder remain under investigation. Identification of the systemic diseases underlying SFN will enable development of drugs that target affected pathways to improve the management of neuropathic pain and autonomic dysfunction. In this Review, we discuss recent advances in the diagnosis and pathophysiology of SFN, highlighting how improved understanding of these aspects of the disorder will contribute to better patient management.
小纤维神经病(SFN)是一种薄髓鞘 Aδ 纤维和无髓鞘 C 纤维的功能障碍,其临床特征为神经性疼痛症状和自主神经症状。SFN 的诊断具有挑战性,因为临床表现难以解读,且神经传导研究的结果通常正常。在疑似 SFN 的情况下,可通过测量表皮内神经纤维密度和/或进行定量感觉测试分析来进行诊断。新的诊断技术(包括使用角膜共聚焦显微镜测量神经纤维密度和伤害感受诱发电位)可能有助于诊断。SFN 可与免疫介导性疾病等系统性疾病相关,但在相当一部分患者中仍为特发性。最近发现,近 30%的特发性 SFN 患者存在 Na(v)1.7 钠离子通道功能获得性变异,但该疾病中轴突退化的机制仍在研究中。确定 SFN 所涉及的系统性疾病将能够开发靶向受影响途径的药物,以改善神经性疼痛和自主神经功能障碍的管理。在这篇综述中,我们讨论了 SFN 的诊断和病理生理学的最新进展,强调了对该疾病这些方面的理解如何有助于更好地管理患者。